PureTech's Founded Entity, Seaport Therapeutics, Announces Topline Data From Portions Of Ongoing Phase 1 Proof-Of-Concept Clinical Trial Evaluating GlyphAgo

PureTech Health plc's Founded Entity, Seaport Therapeutics, has announced positive topline data from its ongoing Phase 1 proof-of-concept clinical trial for GlyphAgo, a novel oral prodrug aimed at treating generalized anxiety disorder (GAD). Following this data, Seaport plans to initiate two parallel trials: a Phase 2a trial to assess sleep benefits and a Phase 2b randomized placebo-controlled trial designed for registration. GlyphAgo represents the second clinical-stage candidate from Seaport's pipeline, which is built on PureTech's strategy of targeted innovation.